Important areas for future research include the following: (1) future studies of dorzagliatin in non‐Asian populations and in a larger population of patients suffering from T2DM and (2) investigations of the possibility of dorzagliatin in combination with other conventional antidiabetic drugs, GLP‐1 receptor agonists, and SGLT2 inhibitors in patients suffering from middle and advanced T2DM, as well as the benefits and limitations of dorzagliatin in alliance with antidiabetic medicines recommended by current clinical guidelines. Here, SLC5A2 is linked to type 2 diabetes mellitus.